This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Cesare, M. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by De Cesare, M. Articles by Zunino, F.

Potent Antitumor Activity and Improved Pharmacological Profile of ST1481, a Novel 7-substituted Camptothecin¹

Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milano [M. D. C., G. P., P. P., N. C., S. T., F. Z.]; Dipartimento di Scienze Molecolari Agroalimentari, Universita’ di Milano, 20133 Milano [L. M., S. P.]; and Sigma-Tau, 00040 Pomezia (Rome) [C. P., F. B., L. V., S. P., F. C., P. C.], Italy

Relevant drawbacks of the molecular structure and mechanism of the action of camptothecins are the instability of the E ring lactone and the reversibility of drug-target interaction. Such features are expected to limit the clinical efficacy of conventional camptothecins. In an attempt to overcome these limitations and to improve the pharmacological profile of camptothecins, a novel series of seven modified lipophilic analogues was synthesized based on the hypothesis that lipophilicity could promote a rapid cellular accumulation and stabilization of drug-target interaction. A novel analogue (ST1481) of the series, characterized by a potent antitopoisomerase and cytotoxic activity, was selected for preclinical development. A detailed preclinical study of ST1481 was performed in the H460 non-small cell lung tumor model using oral administration and various treatment schedules. Under all of the conditions, ST1481 exhibited an impressive efficacy in terms of tumor growth inhibition (tumor volume inhibition percentage > 99%), log₁₀ cell kill, rate of complete responses (including "cures"), and an improvement of the therapeutic index compared with topotecan (used as the reference drug). The cytotoxic potency was also reflected by the in vivo potency, because the drug activity was observed at doses as low as 0.25 mg/kg with the daily schedule. In contrast to topotecan, no cross-resistance to ST1481 was found in ovarian carcinoma cells overexpressing P-glycoprotein (A2780/DX). A similar trend in the improvement of activity was also observed in the same tumor model growing in vivo with a 100% rate of complete tumor regressions. A rapid intestinal absorption and good oral bioavailability were supported by in vivo distribution studies, because the peak values of drug accumulation were found from 1 to 2 h after administration. The relevant liver accumulation may account for a marked effect of ST1481 against liver metastases induced by the ovarian carcinoma IGROV-1. In conclusion, the results support the hypothesis that a potent lipophilic camptothecin with a proper substituent at the position 7 may have therapeutic advantages likely related to a rapid intracellular uptake and tissue distribution, stabilization of the drug-target complex, and good oral bioavailability. Overall, the results support the preclinical interest of ST1481 in terms of efficacy, potency, toxicity profile, and ability to overcome multidrug resistance.

This article has been cited by other articles:

				R. L. Oostendorp, E. van de Steeg, C. M. M. van der Kruijssen, J. H. Beijnen, K. E. Kenworthy, A. H. Schinkel, and J. H. M. Schellens Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors Drug Metab. Dispos., April 1, 2009; 37(4): 917 - 923. [Abstract] [Full Text] [PDF]

				A. X. Zhu, N. Ready, J. W. Clark, H. Safran, A. Amato, N. Salem, S. Pace, X. He, N. Zvereva, T. J. Lynch, et al. Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors Clin. Cancer Res., January 1, 2009; 15(1): 374 - 381. [Abstract] [Full Text] [PDF]

				C. Pisano, M. De Cesare, G. L. Beretta, V. Zuco, G. Pratesi, S. Penco, L. Vesci, R. Fodera, F. F. Ferrara, M. B. Guglielmi, et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968 Mol. Cancer Ther., July 1, 2008; 7(7): 2051 - 2059. [Abstract] [Full Text] [PDF]

				M. Huang, H. Gao, Y. Chen, H. Zhu, Y. Cai, X. Zhang, Z. Miao, H. Jiang, J. Zhang, H. Shen, et al. Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles In vitro and In vivo Clin. Cancer Res., February 15, 2007; 13(4): 1298 - 1307. [Abstract] [Full Text] [PDF]

				M. De Cesare, G. Pratesi, S. Veneroni, R. Bergottini, and F. Zunino Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7357 - 7364. [Abstract] [Full Text] [PDF]

				G. Petrangolini, G. Pratesi, M. De Cesare, R. Supino, C. Pisano, M. Marcellini, V. Giordano, D. Laccabue, C. Lanzi, and F. Zunino Antiangiogenic Effects of the Novel Camptothecin ST1481 (Gimatecan) in Human Tumor Xenografts Mol. Cancer Res., October 1, 2003; 1(12): 863 - 870. [Abstract] [Full Text] [PDF]

				G. Pratesi, M. De Cesare, N. Carenini, P. Perego, S. C. Righetti, C. Cucco, L. Merlini, C. Pisano, S. Penco, P. Carminati, et al. Pattern of Antitumor Activity of a Novel Camptothecin, ST1481, in a Large Panel of Human Tumor Xenografts Clin. Cancer Res., December 1, 2002; 8(12): 3904 - 3909. [Abstract] [Full Text] [PDF]